These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36284039)
1. Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma. Babu D; Chintal R; Panigrahi M; Phanithi PB Cell Oncol (Dordr); 2022 Dec; 45(6):1451-1465. PubMed ID: 36284039 [TBL] [Abstract][Full Text] [Related]
2. Exploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM. Zhao S; Ni K; Xie J; Cheng C; Zhao N; Liu J; Ji W; Wang Q; Zhang P; Liu Y J Neurooncol; 2024 Oct; 170(1):101-117. PubMed ID: 39143438 [TBL] [Abstract][Full Text] [Related]
3. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cicek M; Fukuyama R; Welch DR; Sizemore N; Casey G Cancer Res; 2005 May; 65(9):3586-95. PubMed ID: 15867352 [TBL] [Abstract][Full Text] [Related]
4. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53. Kapoor GS; Christie A; O'Rourke DM Cancer Biol Ther; 2007 Apr; 6(4):571-9. PubMed ID: 17457042 [TBL] [Abstract][Full Text] [Related]
5. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. Liang Y; Bollen AW; Aldape KD; Gupta N BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53. Hall EH; Liu Y; Xiao A; Shock L; Brautigan DL; Mayo MW; Adusumilli PS; Jones DR PLoS One; 2014; 9(4):e95869. PubMed ID: 24763730 [TBL] [Abstract][Full Text] [Related]
7. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma. Shwetha SD; Shastry AH; Arivazhagan A; Santosh V Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112 [TBL] [Abstract][Full Text] [Related]
8. [DNA methylation modification of BRMS1 in triple-negative breast cancer and its correlation with tumor metastasis]. Xia J; Lü ZD; Zhou PH; Cui SC; Kong B; Liu D; Long SS; Zhang XH; Zhao JJ Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3483-3487. PubMed ID: 29275584 [No Abstract] [Full Text] [Related]
9. Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer cell aggressiveness through downregulating HIF-1α expression. Cho KH; Yu SL; Cho DY; Park CG; Lee HY BMC Cancer; 2015 Oct; 15():829. PubMed ID: 26520789 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Li J; Cheng Y; Tai D; Martinka M; Welch DR; Li G Oncogene; 2011 Feb; 30(8):896-906. PubMed ID: 20935672 [TBL] [Abstract][Full Text] [Related]
11. Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression. Sheng XJ; Zhou YQ; Song QY; Zhou DM; Liu QC Oncol Rep; 2012 Apr; 27(4):1011-8. PubMed ID: 22200669 [TBL] [Abstract][Full Text] [Related]
12. Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells. Vaidya KS; Sanchez JJ; Kim EL; Welch DR Cancer Lett; 2009 Aug; 281(1):100-7. PubMed ID: 19307053 [TBL] [Abstract][Full Text] [Related]
13. BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Cicek M; Fukuyama R; Cicek MS; Sizemore S; Welch DR; Sizemore N; Casey G Clin Exp Metastasis; 2009; 26(3):229-37. PubMed ID: 19165610 [TBL] [Abstract][Full Text] [Related]
15. Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status. Memmel S; Sukhorukov VL; Höring M; Westerling K; Fiedler V; Katzer A; Krohne G; Flentje M; Djuzenova CS PLoS One; 2014; 9(1):e87052. PubMed ID: 24498019 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway. Guan Y; He Y; Lv S; Hou X; Li L; Song J J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100 [TBL] [Abstract][Full Text] [Related]
18. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324 [TBL] [Abstract][Full Text] [Related]
19. BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells. Sheng XJ; Zhou DM; Liu Q; Lou SY; Song QY; Zhou YQ Eur J Gynaecol Oncol; 2014; 35(3):236-42. PubMed ID: 24984534 [TBL] [Abstract][Full Text] [Related]
20. Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. Hurst DR; Xie Y; Vaidya KS; Mehta A; Moore BP; Accavitti-Loper MA; Samant RS; Saxena R; Silveira AC; Welch DR J Biol Chem; 2008 Mar; 283(12):7438-44. PubMed ID: 18211900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]